# Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

> **NCT00002869** · PHASE3 · UNKNOWN · sponsor: **Medical Research Council** · enrollment: 800 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cytarabine
- **DRUG:** hydroxyurea

## Key facts

- **NCT ID:** NCT00002869
- **Lead sponsor:** Medical Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1995-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002869, "Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00002869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*